Frequency, duration, and intensity of solicited local adverse events (AEs);Frequency, duration, and intensity of solicited systemic adverse events (AEs);Frequency, duration, and intensity of solicited systemic adverse events (AEs);Frequency of Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest and any AEs leading to study withdrawal at any time;Geometric Mean Titres (GMT) of the serum NAb (Neutralising Antibody) titres to matched SARS-CoV-2 (prototypic strain) by microneutralisation (MN) assay.;Seroresponse rate (SRR), where seroresponse is defined as ≥ 4-fold rise from pre-vaccination, Day 1) by MN assay to matched SARS-CoV-2 (prototypic strain).

Frequency, duration, and intensity of solicited local adverse events (AEs);Frequency, duration, and intensity of solicited systemic adverse events (AEs);Frequency, duration, and intensity of solicited systemic adverse events (AEs);Frequency of Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest and any AEs leading to study withdrawal at any time;Geometric Mean Titres (GMT) of the serum NAb (Neutralising Antibody) titres to matched SARS-CoV-2 (prototypic strain) by microneutralisation (MN) assay.;Seroresponse rate (SRR), where seroresponse is defined as ≥ 4-fold rise from pre-vaccination, Day 1) by MN assay to matched SARS-CoV-2 (prototypic strain).